Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa dose-escalation study of AK0610 in healthy Chinese infants for RSV prevention
CTR20253151Phase 2Active
- Sponsor
- Ark Biosciences
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AK0610 in respiratory syncytial virus disease (RSV), sponsored by Ark Biosciences. Started Sep 2025; status: active.
02
Drugs
AK0610
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20253151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253151.